pre_text: ( a ) excludes discontinued operations . ( b ) earnings before interest expense and taxes as a percent of average total assets . ( c ) total debt as a percent of the sum of total debt , shareholders 2019 equity and non-current deferred income tax liabilities . the results above include the impact of the specified items detailed below . additional discussion regarding the specified items in fiscal years 2017 , 2016 and 2015 are provided in item 7 . management 2019s discussion and analysis of financial condition and results of operations. .
post_text: item 7 . management 2019s discussion and analysis of financial condition and results of operations the following commentary should be read in conjunction with the consolidated financial statements and accompanying notes . within the tables presented throughout this discussion , certain columns may not add due to the use of rounded numbers for disclosure purposes . percentages and earnings per share amounts presented are calculated from the underlying amounts . references to years throughout this discussion relate to our fiscal years , which end on september 30 . company overview description of the company and business segments becton , dickinson and company ( 201cbd 201d ) is a global medical technology company engaged in the development , manufacture and sale of a broad range of medical supplies , devices , laboratory equipment and diagnostic products used by healthcare institutions , life science researchers , clinical laboratories , the pharmaceutical industry and the general public . the company's organizational structure is based upon two principal business segments , bd medical ( 201cmedical 201d ) and bd life sciences ( 201clife sciences 201d ) . bd 2019s products are manufactured and sold worldwide . our products are marketed in the united states and internationally through independent distribution channels and directly to end-users by bd and independent sales representatives . we organize our operations outside the united states as follows : europe ; ema ( which includes the commonwealth of independent states , the middle east and africa ) ; greater asia ( which includes japan and asia pacific ) ; latin america ( which includes mexico , central america , the caribbean , and south america ) ; and canada . we continue to pursue growth opportunities in emerging markets , which include the following geographic regions : eastern europe , the middle east , africa , latin america and certain countries within asia pacific . we are primarily focused on certain countries whose healthcare systems are expanding , in particular , china and india . strategic objectives bd remains focused on delivering sustainable growth and shareholder value , while making appropriate investments for the future . bd management operates the business consistent with the following core strategies : 2022 to increase revenue growth by focusing on our core products , services and solutions that deliver greater benefits to patients , healthcare workers and researchers; .
table: Years Ended September 30
table: Millions of dollars, except per share amounts 2017 2016 2015 2014 2013
table: Total specified items $1,466 $1,261 $1,186 $153 $442
table: After-tax impact of specified items $971 $892 $786 $101 $279
table: Impact of specified items on diluted earnings per share $(4.34) $(4.10) $(3.79) $(0.51) $(1.40)
table: Impact of dilution from share issuances $(0.54) $— $(0.02) $— $—
question: Analyse this data from a financial earnings document. what is the percentage increase for total specified items from 2014-2015?